CD8A and colorectal carcinoma: In addition, we explored the clinical implication of CD8+ Tem, and proposed that CD8+Tem could be regarded as the potential marker for the cetuximab sensitivity, which was validated by the single-cell transcriptome data from CRC patients (GSE108989).